Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. (PLX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
plx · stock forecast · 7 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $1.96
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.94 | ↓ 1.21% |
1-day model range: $1.92–$1.95. Peak: $1.95 (-1.21%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $2 | +25.5% |
| 2028 | $3 | +41.5% |
| 2029 | $3 | +50.5% |
| 2030 | $3 | +55.3% |
| 2031 | — | +57.7% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · PLX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-11-21 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-02-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-11-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-10-31 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2020-06-08 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2017-04-17 | Rodman & Renshaw | Maintains | Buy→Buy |
| 2016-09-06 | Jefferies | Maintains | Buy→Buy |
| 2016-04-04 | Rodman & Renshaw | Maintains | Buy→Buy |
| 2015-04-23 | Jefferies | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Protalix BioTherapeutics, Inc. (PLX) stock. Of the recent 17 rating actions, 0 were upgrades and 1 were downgrades. 7 analysts currently cover PLX.
Analyst Recommendation Trends
PLX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$54M
↓ 31.1% YoY
Revenue Next Year
$62M
↑ 14.9% YoY
EPS This Year
$0.01
EPS Next Year
$0.03
↑ 100.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast PLX EPS of $0.01 for the current fiscal year, based on estimates from 1 analysts. The PLX revenue forecast is $54M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The PLX stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PLX price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The PLX short-term stock prediction for tomorrow is $1.94 (-1.21%). The PLX stock price prediction for 2027 estimates an average of $2. The PLX stock prediction for 2030 projects a range of $3–$3.
Protalix BioTherapeutics, Inc. trades on AMEX under the ticker PLX. The PLX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 71% of covering analysts.
Frequently asked questions
PLX forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month PLX price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $1.96.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.